Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 9/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | DRD5 | P21918 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923619 | 0.91 | DRD3 (0.47) | TDO2DRD2HTR2ADRD3DRD4 | |
| SCHEMBL6925622 | 0.90 | HRH3 (0.45) | DRD2HTR2ADRD3DRD4HTR1A | |
| SCHEMBL6923696 | 0.89 | RET (0.43) | RETZAP70KDM4EGAAHRH4 | |
| SCHEMBL6927079 | 0.88 | TDO2 (0.43) | TDO2DRD2HTR2ADRD3DRD4 | |
| SCHEMBL6927411 | 0.88 | KMT2A (0.47) | DRD4RETZAP70KDM4EGAA | |
| SCHEMBL6926756 | 0.87 | TDO2 (0.58) | TDO2HTR2ADRD3DRD4HTR1A | |
| SCHEMBL6925251 | 0.87 | RET (0.50) | HTR2AHTR1ARETZAP70HTR2C | |
| SCHEMBL6925583 | 0.87 | HTR2A (0.47) | TDO2DRD2HTR2ADRD3DRD4 | |
| SCHEMBL6928854 | 0.86 | MGLL (0.44) | TDO2RETZAP70KDM4EGAA | |
| SCHEMBL6927588 | 0.86 | DRD3 (0.47) | TDO2DRD2HTR2ADRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | TDO2 1269/4885DRD2 1447/4885HTR2A 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.